NEW YORK, NY / ACCESSWIRE / December 7, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
First American Financial Corp. (NYSE:FAF)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/first-american-financial-corp-loss-submission-form?prid=11401&wire=1
Lead Plaintiff Deadline: December 24, 2020
Class Period: February 17, 2017 - October 22, 2020
Allegations against FAF include that: (1) the Company failed to implement basic security standards to protect its customers' sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11401&wire=1
Lead Plaintiff Deadline: January 4, 2021
Class Period: September 28, 2019 - October 7, 2020
Allegations against ICPT include that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.
K12 Inc. (NYSE:LRN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/k12inc-loss-submission-form?prid=11401&wire=1
Lead Plaintiff Deadline: January 19, 2021
Class Period: April 27, 2020 - September 18, 2020
Allegations against LRN include that: (i) K12 lacked the technological capabilities, infrastructures, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (ii) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer system; (iii) K12 was unable provide the necessary levels of administrative support and training to teachers, students, and parents; and (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted facts.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/619825/SHAREHOLDER-ALERT-FAF-ICPT-LRN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
